Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 5Thoracic 4Breast 4Plasma cell 3Myeloid 3Head & Neck 3Classical hematology 3Other 2Lymphoid 2Genitourinary 2Gastrointestinal 2Other neoplasm 1Other hematologic neoplasm 1NET 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors 208Multiple Endocrine Neoplasia Type 1 130Thyroid Cancer, Papillary 78Pituitary Neoplasms 70Thyroid Neoplasms 59Pheochromocytoma 55Carcinoma, Neuroendocrine 49Neoplasms 48Carcinoid Tumor 48Carcinoma, Medullary 35Adrenocortical Carcinoma 35Adenocarcinoma, Follicular 34Pancreatic Neoplasms 33Thyroid Carcinoma, Anaplastic 30Neoplasm Metastasis 27Carcinoma, Non-Small-Cell Lung 27Insulinoma 26Breast Neoplasms 25Paraganglioma 24Melanoma 23Colorectal Neoplasms 23Colonic Neoplasms 23Carcinoma, Renal Cell 23Adenoma, Islet Cell 23Somatostatinoma 22Adrenal Gland Neoplasms 22Sarcoma 21Carcinoma, Islet Cell 21Prostatic Neoplasms 20Glucagonoma 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hypersensitivity × Endocrine × Clear all
NCT01673906 2025-06-24

68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours

Azienda USL Reggio Emilia - IRCCS

Phase 2 Completed
142 enrolled
EndocrineNET

Hypersensitivity, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡